Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
801
Exelixis
EXEL
$12.5B
| $19.5M | 0.03% |
1,310,510
-557,940
| -30% | -$8.05M |
|
802
Cohen & Steers
CNS
$4.36B
| $19.5M | 0.03% |
581,300
+91,100
| +19% | +$3.33M |
|
803
Kaiser Aluminum
KALU
$2.99B
| $19.5M | 0.03% |
251,000
-45,300
| -15% | -$3.62M |
|
804
Seaboard Corp
SEB
$4.02B
| $19.5M | 0.03% |
4,926
-208
| -4% | -$786K |
|
805
Gran Tierra Energy
GTE
$331M
| $19.5M | 0.03% |
644,110
-44,170
| -6% | -$1.31M |
|
806
KBR
KBR
$4.8B
| $19.4M | 0.03% |
1,161,200
-546,075
| -32% | -$8.69M |
|
|
CKH
807
DELISTED
Seacor Holdings Inc.
CKH
| $19.4M | 0.03% |
280,834
+46,219
| +20% | +$2.72M |
|
808
Accuray
ARAY
$32.9M
| $19.4M | 0.03% |
4,207,500
-79,223
| -2% | -$411K |
|
|
SJR
809
DELISTED
Shaw Communications Inc.
SJR
| $19.3M | 0.03% |
964,300
-249,300
| -21% | -$4.95M |
|
810
Lazard
LAZ
$4.24B
| $19.3M | 0.03% |
469,500
+420,500
| +858% | +$16.3M |
|
|
NUTR
811
DELISTED
Nutraceutical International Co
NUTR
| $19.3M | 0.03% |
551,500
+21,300
| +4% | +$675K |
|
812
Enanta Pharmaceuticals
ENTA
$393M
| $19.3M | 0.03% |
574,771
-126,629
| -18% | -$3.63M |
|
|
EVHC
813
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $19.2M | 0.03% |
303,972
+227,853
| +299% | +$14.9M |
|
814
Elbit Systems
ESLT
$36.5B
| $19.2M | 0.03% |
188,735
+28,900
| +18% | +$2.88M |
|
815
Mattel
MAT
$4.19B
| $19.2M | 0.03% |
+697,300
| New | +$21.2M |
|
|
BFS
816
Saul Centers
BFS
$850M
| $19.2M | 0.03% |
288,300
+27,800
| +11% | +$1.77M |
|
|
ZAYO
817
DELISTED
Zayo Group Holdings, Inc.
ZAYO
| $19.2M | 0.03% |
583,700
+212,500
| +57% | +$6.96M |
|
|
NSU
818
DELISTED
Nevsun Resources Ltd.
NSU
| $19.2M | 0.03% |
6,207,600
+1,115,800
| +22% | +$3.38M |
|
|
EXK
819
Endeavour Silver
EXK
$3.14B
| $19.2M | 0.03% |
5,447,300
+401,100
| +8% | +$1.62M |
|
|
BKMU
820
DELISTED
Bank Mutual Corp
BKMU
| $19.1M | 0.03% |
2,026,323
+300,870
| +17% | +$2.55M |
|
|
SFR
821
DELISTED
Starwood Waypoint Homes
SFR
| $19.1M | 0.03% |
663,800
-419,000
| -39% | -$12.2M |
|
|
SCLN
822
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
| $19.1M | 0.03% |
1,769,898
+384,898
| +28% | +$3.85M |
|
823
Barclays
BCS
$94.4B
| $19M | 0.03% |
1,832,834
+566,338
| +45% | +$5.34M |
|
|
PARAA
824
DELISTED
Paramount Global Class A
PARAA
| $19M | 0.03% |
293,200
+400
| +0.1% | +$24K |
|
825
Park Aerospace
PKE
$828M
| $19M | 0.03% |
1,017,900
+58,200
| +6% | +$993K |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.